bevacizumab + carboplatin + nab-paclitaxel

The combination of bevacizumab, carboplatin, and nab-paclitaxel is a chemotherapy regimen used primarily for the treatment of non-squamous non-small cell lung cancer (NSCLC). This combination has shown good efficacy with acceptable toxicity profiles in clinical trials. ## Composition and Mechanism This regimen combines three distinct agents: 1. **Bevacizumab**: A monoclonal antibody that inhibits angiogenesis by targeting vascular epidermal growth factor (VEGF)[5] 2. **Carboplatin**: A platinum-based chemotherapy drug that destroys quickly dividing cells[7] 3. **Nab-paclitaxel**: A nanoparticle albumin-bound form of paclitaxel that exhibits an improved toxicity profile compared to conventional paclitaxel[2] ## Clinical Evidence Clinical studies have demonstrated the effectiveness of this combination: - A retrospective analysis showed a best response rate of 56.3% and a disease control rate of 79.2% in non-squamous NSCLC patients[1] - Median progression-free survival was 6.8 months and overall survival was 10.4 months in one study[1] - A Phase I/II trial in Japanese patients established a dosage schedule of carboplatin (AUC=6 on Day 1) + nab-paclitaxel (100 mg/m² on Days 1, 8, and 15) + bevacizumab (15 mg/kg on Day 1)[2] - The overall response rate in the Japanese study was 56.5%, with 93% of patients showing tumor shrinkage or stable disease[2] ## Administration The typical administration schedule involves: - 4-6 cycles of the triple combination therapy - Followed by maintenance therapy with bevacizumab plus nab-paclitaxel without disease progression or severe toxicities[1][2] ## Safety Profile Common adverse events include: - Hematological toxicities, particularly neutropenia (Grade ≥3 in 72% of patients in one study)[2] - Leukopenia (50%) and anemia (30%)[2] - Neurosensory toxicity[1] - Rare but serious events such as gastrointestinal bleeding[1] The combination has shown to be well-tolerated in Japanese patients as first-line treatment for advanced non-squamous NSCLC, with manageable adverse effects[2].

Other names

BCPBev plus CBDCA/nab-PTX